| NCT03406299 |
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03406299 |
Recruiting |
National Health Research Institutes, Taiwan |
2020-06-30 |
| NCT03358849 |
Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell (“SMT-NK”) Cell Therapy in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03358849 |
Completed |
Yonsei University |
2018-09-27 |
| NCT03314935 |
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03314935 |
Recruiting |
Incyte Corporation |
2021-10-06 |
| NCT03291899 |
Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT03291899 |
Recruiting |
King Faisal Specialist Hospital & Research Center |
2019-08-31 |
| NCT03278106 |
TAS-102 in Treating Advanced Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT03278106 |
Active, not recruiting |
Mayo Clinic |
2018-11-30 |
| NCT03260712 |
Pembrolizumab in Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03260712 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2022-11-01 |
| NCT03231176 |
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03231176 |
Active, not recruiting |
Aslan Pharmaceuticals |
2020-03-31 |
| NCT03185988 |
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System |
https://ClinicalTrials.gov/show/NCT03185988 |
Recruiting |
Peking University |
2021-07-31 |
| NCT03162510 |
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers |
https://ClinicalTrials.gov/show/NCT03162510 |
Recruiting |
National Health Research Institutes, Taiwan |
2021-12-31 |
| NCT03111732 |
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) |
https://ClinicalTrials.gov/show/NCT03111732 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2020-12-31 |
| NCT03110328 |
Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes |
https://ClinicalTrials.gov/show/NCT03110328 |
Recruiting |
Samsung Medical Center |
2020-08-31 |
| NCT03101566 |
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03101566 |
Active, not recruiting |
University of Michigan Rogel Cancer Center |
2019-12-03 |
| NCT03093870 |
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03093870 |
Active, not recruiting |
Aslan Pharmaceuticals |
2019-07-31 |
| NCT02293954 |
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer |
https://ClinicalTrials.gov/show/NCT02293954 |
Active, not recruiting |
City of Hope Medical Center |
2020-06-30 |
| NCT03082053 |
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours |
https://ClinicalTrials.gov/show/NCT03082053 |
Completed |
Aslan Pharmaceuticals |
2017-12-07 |
| NCT03079427 |
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma |
https://ClinicalTrials.gov/show/NCT03079427 |
Recruiting |
Asan Medical Center |
2021-04-30 |
| NCT03044587 |
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer |
https://ClinicalTrials.gov/show/NCT03044587 |
Recruiting |
AIO-Studien-gGmbH |
2019-12-31 |
| NCT02992340 |
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC |
https://ClinicalTrials.gov/show/NCT02992340 |
Recruiting |
Aslan Pharmaceuticals |
2020-06-30 |
| NCT02988635 |
Early Palliative Care on Quality of Life of Advanced Cancer Patients |
https://ClinicalTrials.gov/show/NCT02988635 |
Completed |
Azienda Ospedaliero-Universitaria di Parma |
2016-11-30 |
| NCT02966821 |
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma |
https://ClinicalTrials.gov/show/NCT02966821 |
Completed |
Hutchison Medipharma Limited |
2018-08-17 |
| NCT02943031 |
The Effect of Individualized Precision Therapy Programs in Patients With BTC |
https://ClinicalTrials.gov/show/NCT02943031 |
Recruiting |
RenJi Hospital |
2020-12-31 |
| NCT02908451 |
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer |
https://ClinicalTrials.gov/show/NCT02908451 |
Recruiting |
AbGenomics B.V Taiwan Branch |
2020-10-31 |
| NCT02866383 |
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients |
https://ClinicalTrials.gov/show/NCT02866383 |
Recruiting |
Herlev Hospital |
2020-11-30 |
| NCT02829918 |
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT02829918 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2019-03-27 |
| NCT02821754 |
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) |
https://ClinicalTrials.gov/show/NCT02821754 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2020-12-31 |
| NCT02773459 |
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02773459 |
Completed |
Seoul National University Hospital |
2019-01-07 |
| NCT02711553 |
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02711553 |
Active, not recruiting |
Eli Lilly and Company |
2018-02-16 |
| NCT02703714 |
Pembrolizumab and GM-CSF in Biliary Cancer |
https://ClinicalTrials.gov/show/NCT02703714 |
Active, not recruiting |
University of California, San Francisco |
2020-05-31 |
| NCT02670265 |
Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions |
https://ClinicalTrials.gov/show/NCT02670265 |
Completed |
University Medicine Greifswald |
2014-02-28 |
| NCT02632305 |
A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02632305 |
Recruiting |
AHS Cancer Control Alberta |
2020-01-31 |
| NCT02586987 |
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours |
https://ClinicalTrials.gov/show/NCT02586987 |
Completed |
AstraZeneca |
2018-07-25 |
| NCT02443324 |
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02443324 |
Active, not recruiting |
Eli Lilly and Company |
2018-08-31 |
| NCT04298021 |
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04298021 |
Recruiting |
Seoul National University Hospital |
2021-03-31 |
| NCT04298008 |
AZD6738 Plus Durvalumab in Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04298008 |
Recruiting |
Seoul National University Hospital |
2021-03-31 |
| NCT02558959 |
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02558959 |
Completed |
Zhejiang University |
2017-09-30 |
| NCT01758341 |
Radiofrequency Ablation for Malignant Biliary Obstruction |
https://ClinicalTrials.gov/show/NCT01758341 |
Completed |
Medical University of Vienna |
2013-05-31 |
| NCT02489422 |
Programs To Support You During Chemotherapy |
https://ClinicalTrials.gov/show/NCT02489422 |
Completed |
Wake Forest University Health Sciences |
2020-01-31 |
| NCT02433639 |
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02433639 |
Completed |
Seoul National University Hospital |
2017-10-31 |
| NCT02425137 |
A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02425137 |
Completed |
TTY Biopharm |
2017-05-31 |
| NCT02386397 |
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02386397 |
Completed |
Institut du Cancer de Montpellier - Val d’Aurelle |
2019-12-31 |
| NCT02351765 |
ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT02351765 |
Completed |
The Christie NHS Foundation Trust |
2019-03-31 |
| NCT02350686 |
XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy |
https://ClinicalTrials.gov/show/NCT02350686 |
Recruiting |
Samsung Medical Center |
2019-12-31 |
| NCT02346032 |
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02346032 |
Completed |
Samsung Medical Center |
2016-09-30 |
| NCT02182778 |
GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02182778 |
Completed |
Kansai Hepatobiliary Oncology Group |
2016-02-04 |
| NCT02146703 |
Gemcitabine and S-1 for Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT02146703 |
Completed |
Hallym University Medical Center |
2010-11-30 |
| NCT02102984 |
Covered Versus Uncovered Biliary Stents for Biliary Malignancies |
https://ClinicalTrials.gov/show/NCT02102984 |
Completed |
Nuovo Ospedale Civile S.Agostino Estense |
2015-09-30 |
| NCT01315522 |
Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents |
https://ClinicalTrials.gov/show/NCT01315522 |
Completed |
Seoul National University Hospital |
2014-11-30 |
| NCT01308840 |
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer |
https://ClinicalTrials.gov/show/NCT01308840 |
Completed |
University of Rochester |
2013-01-31 |
| NCT01297998 |
A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy |
https://ClinicalTrials.gov/show/NCT01297998 |
Completed |
Kansai Hepatobiliary Oncology Group |
2012-12-31 |
| NCT01291615 |
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01291615 |
Completed |
Kansai Hepatobiliary Oncology Group |
2012-10-31 |
| NCT01284413 |
Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01284413 |
Completed |
Kansai Hepatobiliary Oncology Group |
2012-08-31 |
| NCT02002806 |
Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control |
https://ClinicalTrials.gov/show/NCT02002806 |
Completed |
Indiana University |
2018-12-31 |
| NCT01943864 |
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT01943864 |
Completed |
GlaxoSmithKline |
2014-07-01 |
| NCT01926236 |
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT01926236 |
Completed |
The Christie NHS Foundation Trust |
2018-01-05 |
| NCT01853618 |
Tremelimumab With Chemoembolization or Ablation for Liver Cancer |
https://ClinicalTrials.gov/show/NCT01853618 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-06-07 |
| NCT01821248 |
A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis |
https://ClinicalTrials.gov/show/NCT01821248 |
Active, not recruiting |
Kansai Hepatobiliary Oncology Group |
2016-09-27 |
| NCT01815307 |
Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01815307 |
Completed |
Kansai Hepatobiliary Oncology Group |
2016-05-31 |
| NCT01731821 |
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy |
https://ClinicalTrials.gov/show/NCT01731821 |
Completed |
Fudan University |
2014-06-30 |
| NCT01713387 |
A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy |
https://ClinicalTrials.gov/show/NCT01713387 |
Completed |
Kansai Hepatobiliary Oncology Group |
2015-04-30 |
| NCT01661114 |
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers |
https://ClinicalTrials.gov/show/NCT01661114 |
Completed |
University of Michigan Rogel Cancer Center |
2014-12-31 |
| NCT01595217 |
MRCP Diagnoses EHCC Better When Combined DWI |
https://ClinicalTrials.gov/show/NCT01595217 |
Completed |
China Medical University, China |
2013-03-31 |
| NCT01589328 |
Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB |
https://ClinicalTrials.gov/show/NCT01589328 |
Completed |
National Cancer Center, Korea |
2017-06-30 |
| NCT01572324 |
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas |
https://ClinicalTrials.gov/show/NCT01572324 |
Completed |
Peking University |
2015-10-31 |
| NCT01530503 |
Second Line Therapy in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01530503 |
Completed |
IRCCS San Raffaele |
2013-10-31 |
| NCT01375972 |
Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT01375972 |
Completed |
Asan Medical Center |
2011-07-31 |
| NCT04333927 |
Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer |
https://ClinicalTrials.gov/show/NCT04333927 |
Active, not recruiting |
Sun Yat-sen University |
2024-06-30 |
| NCT04329429 |
A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer. |
https://ClinicalTrials.gov/show/NCT04329429 |
Recruiting |
RemeGen |
2022-08-01 |
| NCT04318834 |
Molecular Profiling of Advanced Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT04318834 |
Recruiting |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2022-04-30 |
| NCT04308174 |
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04308174 |
Recruiting |
Asan Medical Center |
2021-09-30 |
| NCT04300959 |
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04300959 |
Recruiting |
Zhejiang Cancer Hospital |
2021-01-31 |
| NCT04238637 |
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) |
https://ClinicalTrials.gov/show/NCT04238637 |
Recruiting |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2023-12-31 |
| NCT04234113 |
Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT04234113 |
Recruiting |
Sotio a.s. |
2022-03-31 |
| NCT04203160 |
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) |
https://ClinicalTrials.gov/show/NCT04203160 |
Recruiting |
University of Michigan Rogel Cancer Center |
2024-06-30 |
| NCT04186156 |
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04186156 |
Active, not recruiting |
Karus Therapeutics Limited |
2023-03-31 |
| NCT04172402 |
NGS as the First-line Treatment in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04172402 |
Recruiting |
National Health Research Institutes, Taiwan |
2022-12-31 |
| NCT04163900 |
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04163900 |
Recruiting |
NuCana plc |
2023-12-31 |
| NCT04111380 |
Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT04111380 |
Recruiting |
Henan Provincial People’s Hospital |
2023-03-31 |
| NCT04072445 |
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04072445 |
Recruiting |
Mayo Clinic |
2021-05-15 |
| NCT04057365 |
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) |
https://ClinicalTrials.gov/show/NCT04057365 |
Recruiting |
Massachusetts General Hospital |
2022-08-31 |
| NCT04027764 |
Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT04027764 |
Recruiting |
Chinese PLA General Hospital |
2020-05-01 |
| NCT04005339 |
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer |
https://ClinicalTrials.gov/show/NCT04005339 |
Recruiting |
Georgetown University |
2021-07-31 |
| NCT04004234 |
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC |
https://ClinicalTrials.gov/show/NCT04004234 |
Recruiting |
Chinese PLA General Hospital |
2020-08-31 |
| NCT03943043 |
Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03943043 |
Recruiting |
Istituto Clinico Humanitas |
2020-05-01 |
| NCT03937895 |
Allogeneic NK Cell (“SMT-NK”) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03937895 |
Recruiting |
SMT bio Co., Ltd. |
2021-02-02 |
| NCT03875235 |
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) |
https://ClinicalTrials.gov/show/NCT03875235 |
Recruiting |
AstraZeneca |
2022-06-30 |
| NCT03873532 |
A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT03873532 |
Recruiting |
Hutchison Medipharma Limited |
2021-06-30 |
| NCT03833661 |
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) |
https://ClinicalTrials.gov/show/NCT03833661 |
Active, not recruiting |
EMD Serono |
2020-11-09 |
| NCT03830606 |
The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT03830606 |
Recruiting |
Chinese Academy of Medical Sciences |
2019-03-02 |
| NCT03801083 |
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT03801083 |
Recruiting |
University of Pittsburgh |
2021-01-31 |
| NCT03796429 |
A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03796429 |
Recruiting |
Shanghai Zhongshan Hospital |
2022-12-01 |
| NCT03790111 |
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03790111 |
Recruiting |
Lexicon Pharmaceuticals |
2020-12-31 |
| NCT03785873 |
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03785873 |
Recruiting |
University of Michigan Rogel Cancer Center |
2023-05-31 |
| NCT03779035 |
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection |
https://ClinicalTrials.gov/show/NCT03779035 |
Recruiting |
Tianjin Medical University Cancer Institute and Hospital |
2020-12-31 |
| NCT03768414 |
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT03768414 |
Recruiting |
Southwest Oncology Group |
2024-01-01 |
| NCT03673072 |
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC |
https://ClinicalTrials.gov/show/NCT03673072 |
Recruiting |
Krankenhaus Nordwest |
2024-11-30 |
| NCT03639935 |
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy |
https://ClinicalTrials.gov/show/NCT03639935 |
Recruiting |
University of Michigan Rogel Cancer Center |
2022-01-31 |
| NCT03631173 |
Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy |
https://ClinicalTrials.gov/show/NCT03631173 |
Recruiting |
Oslo University Hospital |
2020-06-01 |
| NCT03613168 |
Trastuzumab in HER2-positive Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03613168 |
Recruiting |
Asan Medical Center |
2020-09-01 |
| NCT03531320 |
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase |
https://ClinicalTrials.gov/show/NCT03531320 |
Recruiting |
InnoPharmax Inc. |
2019-10-31 |
| NCT03524508 |
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03524508 |
Active, not recruiting |
Asan Medical Center |
2020-08-31 |
| NCT03482102 |
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03482102 |
Recruiting |
Massachusetts General Hospital |
2021-10-31 |
| NCT03478488 |
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC |
https://ClinicalTrials.gov/show/NCT03478488 |
Recruiting |
3D Medicines (Sichuan) Co., Ltd. |
2021-12-31 |
| NCT03475953 |
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors |
https://ClinicalTrials.gov/show/NCT03475953 |
Recruiting |
Institut Bergonié |
2020-11-30 |
| NCT03464968 |
mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line |
https://ClinicalTrials.gov/show/NCT03464968 |
Recruiting |
Seoul National University Bundang Hospital |
2019-12-25 |
| NCT03427242 |
Apatinib for Advanced Biliary Carcinoma |
https://ClinicalTrials.gov/show/NCT03427242 |
Recruiting |
Fudan University |
2021-10-31 |
| NCT03411200 |
Patient Activation Through Counseling, Exercise and Mobilization |
https://ClinicalTrials.gov/show/NCT03411200 |
Recruiting |
Herlev and Gentofte Hospital |
2020-05-01 |
| NCT01242605 |
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01242605 |
Completed |
University College, London |
2013-03-31 |
| NCT01216345 |
Cetuximab + Gemox in Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01216345 |
Completed |
Association of Research on the Biology of Liver Tumors |
2008-10-31 |
| NCT01127555 |
Salvage mFOLFOX in BTC After Failure of Gemcitabine |
https://ClinicalTrials.gov/show/NCT01127555 |
Completed |
Chung-Ang University |
2012-06-30 |
| NCT00987766 |
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer |
https://ClinicalTrials.gov/show/NCT00987766 |
Completed |
Vanderbilt-Ingram Cancer Center |
2013-07-31 |
| NCT00980889 |
RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction |
https://ClinicalTrials.gov/show/NCT00980889 |
Completed |
Stockholm South General Hospital |
2012-06-30 |
| NCT00939848 |
Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers |
https://ClinicalTrials.gov/show/NCT00939848 |
Completed |
University College, London |
2012-09-30 |
| NCT04352023 |
Analgesic Efficacy After Pancreatobiliary Surgery: Intravenous Versus Patient-controlled Epidural |
https://ClinicalTrials.gov/show/NCT04352023 |
Active, not recruiting |
National Cancer Center, Korea |
2020-04-30 |
| NCT04066491 |
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) |
https://ClinicalTrials.gov/show/NCT04066491 |
Recruiting |
EMD Serono |
2022-11-24 |
| NCT00832689 |
Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00832689 |
Completed |
Yonsei University |
2010-02-28 |
| NCT01917617 |
Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT01917617 |
Completed |
Kansai Hepatobiliary Oncology Group |
2016-01-07 |
| NCT01825603 |
ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT01825603 |
Completed |
University of Nebraska |
2017-06-30 |
| NCT03046862 |
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT03046862 |
Recruiting |
Seoul National University Hospital |
2020-05-31 |
| NCT02579616 |
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy |
https://ClinicalTrials.gov/show/NCT02579616 |
Completed |
Eisai Inc. |
2019-03-27 |
| NCT02784353 |
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy |
https://ClinicalTrials.gov/show/NCT02784353 |
Recruiting |
Asan Medical Center |
2019-12-31 |
| NCT03797326 |
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) |
https://ClinicalTrials.gov/show/NCT03797326 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2024-02-24 |
| NCT00753675 |
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00753675 |
Completed |
Sanofi |
2012-09-30 |
| NCT00747097 |
Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study |
https://ClinicalTrials.gov/show/NCT00747097 |
Completed |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2010-09-30 |
| NCT00626158 |
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers |
https://ClinicalTrials.gov/show/NCT00626158 |
Completed |
University of California, San Francisco |
2010-12-31 |
| NCT00553332 |
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00553332 |
Completed |
National Cancer Institute (NCI) |
2013-01-31 |
| NCT00552149 |
Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin |
https://ClinicalTrials.gov/show/NCT00552149 |
Completed |
Gustave Roussy, Cancer Campus, Grand Paris |
2012-04-30 |
| NCT00423254 |
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. |
https://ClinicalTrials.gov/show/NCT00423254 |
Completed |
Mannkind Corporation |
2009-09-30 |
| NCT00422409 |
Endoscopic Stenting of Gastrointestinal Cancer |
https://ClinicalTrials.gov/show/NCT00422409 |
Completed |
Oslo University Hospital |
2009-04-30 |
| NCT00380588 |
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00380588 |
Completed |
Eli Lilly and Company |
2008-10-31 |
| NCT00363584 |
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00363584 |
Completed |
National Cancer Institute (NCI) |
2013-08-31 |
| NCT00361231 |
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer |
https://ClinicalTrials.gov/show/NCT00361231 |
Completed |
Massachusetts General Hospital |
2009-03-31 |
| NCT00338988 |
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma |
https://ClinicalTrials.gov/show/NCT00338988 |
Completed |
M.D. Anderson Cancer Center |
2009-05-31 |
| NCT00268840 |
The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer |
https://ClinicalTrials.gov/show/NCT00268840 |
Completed |
ARCAGY/ GINECO GROUP |
2006-02-28 |
| NCT00196105 |
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) |
https://ClinicalTrials.gov/show/NCT00196105 |
Completed |
Cook Group Incorporated |
2006-12-31 |
| NCT00174564 |
EXIBIT: Oxaliplatin in Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00174564 |
Completed |
Sanofi |
2006-09-30 |
| NCT00142480 |
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer |
https://ClinicalTrials.gov/show/NCT00142480 |
Completed |
Massachusetts General Hospital |
2007-07-31 |
| NCT00123825 |
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00123825 |
Completed |
Dana-Farber Cancer Institute |
2007-10-31 |
| NCT00073905 |
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer |
https://ClinicalTrials.gov/show/NCT00073905 |
Completed |
Swiss Group for Clinical Cancer Research |
2006-06-30 |